The pharma partner has received worldwide rights to the development and commercialization of three antibodies generated by AnaptysBio using the SHM-XEL platform, under the collaboration.
AnaptysBio is eligible to receive milestone payments and royalties upon development and sale of any products derived from the partnership, in addition to upfront and success fees already received.
AnaptysBio executive chairman James Topper said their SHM-XEL platform continues to deliver high-affinity therapeutic antibodies to a variety of therapeutic targets.
"Recent advances in the SHM-XEL platform permitted AnaptysBio to achieve this milestone in a rapid timeframe, and generate numerous antibodies surpassing the design goals required by our pharma partner," Topper said.